Q1 2026 Earnings — Reported May 11, 2026 · ABCL635 Positive Phase 1 Data · Phase 2 Initiated
Revenue +98% to $8.3M · EPS Beat · ABCL635 Phase 1 Positive · Phase 2 Efficacy Data Q3
AbCellera reported Q1 2026 results with revenue of $8.3M (+98% YoY), beating the $7.55M consensus. EPS loss of −$0.14 beat the −$0.20 estimate. The headline story: positive interim Phase 1 data for ABCL635 — the potential first-in-class non-hormonal antibody for menopausal vasomotor symptoms (hot flashes) — enabling initiation of a Phase 2 clinical trial. ABCL635 showed no liver toxicity, robust NK3R target engagement, and dose-dependent suppression of hot flashes with a convenient monthly or quarterly dosing profile. Phase 2 top-line efficacy and safety data are expected Q3 2026 — the pivotal catalyst for the stock. Cash runway remains strong at $655M total liquidity.
Key Metrics — Q1 2026 Actuals (Official 8-K SEC Filing · May 11, 2026)
Revenue
$8.3M
+98% YoY vs $4.2M
R&D Expenses
$46.7M
Pipeline investment
SG&A Expenses
$12.3M
Reduced vs prior
Net Loss
−$43.2M
−$0.14/share
Cash & Securities
$531M
Operational liquidity
Total Available Liquidity
$655M
Incl. $124M govt. funding
EPS Beat
+$0.06
−$0.14 actual vs −$0.20 consensus
Revenue Beat
+10%
$8.3M vs $7.55M consensus
Key Catalyst: Ph2 Data
Q3 2026
ABCL635 efficacy + safety top-line
Analyst Price Target
$9.86
vs ~$4.95 stock · +99% implied upside
Beat / Miss Matrix
Positives
RevenueEst. $7.55M$8.3M (+10%) · +98% YoY
EPS (Loss)Est. −$0.20−$0.14 (better by $0.06)
ABCL635 Phase 1 safety—No liver toxicity · favorable profile
ABCL635 target engagement—Robust NK3R reduction · dose-dependent
Phase 2 initiation—Enabled by Phase 1 data · started Q2
Total available liquidity—$655M · runway through catalysts
Concerns
Net Loss—−$43.2M · high R&D burn
Deferred RevenuePrior $13.5MDropped to $7.7M
Partner-led programs—Reduction in downstream programs
Cash QoQ—Declined QoQ · operating outflow
Revenue concentration—Low absolute revenue; lumpy recognition
Binary Phase 2 risk—Q3 data miss would be severe
P&L Summary — Q1 2026 vs Q1 2025 (Official 8-K SEC Filing)
Select Financial Results — Three Months Ended March 31, 2026
Revenue$8.3M$4.2M+98%
R&D Expenses$46.7M—Pipeline investment
SG&A Expenses$12.3M—Reduced vs prior
Net Loss−$43.2M—Cash consuming
Net Loss per Share (basic)−$0.14—Beat −$0.20 est.
Deferred Revenue (end Q1)$7.7M$13.5M Q4 2025−43% QoQ
Cash & Marketable Securities$531M—Core liquidity
Non-dilutive govt. funding (unused)$124M—Available
Total Available Liquidity$655M—Strong runway
TTM Revenue$75.1M—Trailing 12 months
P/S Ratio (current)20.1xIndustry: 3.5xPremium multiple
Pipeline Status & CEO Quote
Clinical Pipeline — Status as of Q1 2026
ABCL635
Non-hormonal antibody targeting NK3R for moderate-to-severe vasomotor symptoms (hot flashes) of menopause. Phase 1 positive — no liver toxicity, robust NK3R engagement, favorable PK/PD. Phase 2 initiated Q2 2026.
Phase 1/2
ABCL-575
Undisclosed indication · Phase 1 top-line data expected Q4 2026.
Phase 1
ABCL-688
Undisclosed indication · clinical trial initiation targeted 2027.
Pre-clinical
ABCL-386
Undisclosed indication · clinical trial initiation targeted 2027.
Pre-clinical
Partner Programs
Multiple partnered antibody programs in various stages, generating royalties and milestones.
Platform
ABCL635 Phase 1 Key Data
Mechanism of actionNK3R antibody · non-hormonal
Safety profileNo liver toxicity observed · favorable
Target engagementRobust · potent · sustained NK3R reduction
Doses tested (Ph1)300mg, 600mg, 900mg single dose
Dosing advantageMonthly or quarterly · vs daily pills
Phase 2 statusInitiated Q2 2026
Phase 2 top-line data expectedQ3 2026 · pivotal catalyst
"We are excited to share interim Phase 1 data that show ABCL635 achieved robust NK3R target engagement, demonstrated a favorable safety and tolerability profile with no observed liver toxicity, and has pharmacokinetic properties that support convenient dosing — monthly or potentially even quarterly — that is well-suited to a commercial antibody therapy. These data enabled us to begin the Phase 2 portion of the trial this quarter. Phase 2 top-line efficacy and safety data remain on track for Q3, which we believe is a significant catalyst for the program and for AbCellera."
Carl L. Hansen, Ph.D., President & CEO · Q1 2026 Earnings Call, May 11, 2026
Positives & Concerns
Positives
▲ABCL635 Phase 1 data showed no liver toxicity — the most feared adverse event for NK3R-targeting small molecules. The first-in-class antibody modality may represent a fundamentally safer approach to the clinically validated NK3R pathway. Fezolinetant (Veozah, AZ), the approved small molecule NK3R antagonist, carries a liver toxicity warning that has limited its commercial adoption.
▲Robust and sustained NK3R target engagement biomarker response across all three dose levels (300, 600, 900 mg) — confirming the antibody is reaching and engaging the intended biological target in the hypothalamus. This mechanistic proof-of-concept is the prerequisite for Phase 2 efficacy, and it has now been demonstrated.
▲Convenient monthly or potentially quarterly dosing via injection — versus daily oral pills for competing small molecule NK3R antagonists — creates a meaningful differentiation in a market where adherence is a significant clinical challenge. A long-acting injectable antibody for menopausal hot flashes would occupy an underserved market position.
▲$655M in total available liquidity — including $531M in cash/securities and $124M in non-dilutive Canadian government funding — provides runway well beyond the Q3 2026 Phase 2 readout. AbCellera does not need to raise capital to reach its most important near-term catalyst, eliminating the dilution risk that typically weighs on clinical-stage biotechs.
▲Platform infrastructure investments are substantially complete — the built-out antibody discovery and development infrastructure (including MANA Therapeutics facility) now supports the full pipeline without further major capital expenditure. This means R&D spending going forward is more directly tied to clinical programs rather than facility buildout.
Concerns
▼Phase 2 efficacy data in Q3 2026 is a binary catalyst — if ABCL635 fails to demonstrate statistically significant reduction in hot flash frequency or severity versus placebo, the stock would face a severe decline. Phase 1 data confirmed target engagement but did not measure clinical efficacy (reduction in actual hot flashes). The Q3 efficacy readout is the only metric that matters for the investment thesis.
▼Net loss of $43.2M on $8.3M revenue — a 5.2x loss-to-revenue ratio — reflects the fundamental economics of a pre-commercial clinical-stage biotech. R&D expenses of $46.7M far exceed revenue, and without partnership milestones or royalties from approved products, the company depends entirely on capital markets and government funding for survival.
▼Deferred revenue dropped to $7.7M from $13.5M in Q4 2025 — a 43% QoQ decline. This reflects reduced partner commitments and milestone payments in the near term, signaling that AbCellera's revenue base is narrowing toward internal programs rather than expanding through external partnerships.
▼The stock trades at a P/S ratio of 20.1x TTM revenue versus an industry median of 3.5x — pricing in significant future value that depends entirely on ABCL635 Phase 2 success. Any delay, safety signal, or efficacy miss in the Phase 2 would collapse the premium multiple quickly toward fundamental cash value.
▼AbCellera has reduced partner-led programs with downstream revenue — a concerning trend for the discovery platform thesis. The company's original business model was generating milestone and royalty revenue from partnered antibodies; if that model is underperforming, the valuation must rely almost entirely on ABCL635's commercial potential as a standalone product.
Analyst Coverage — Post Q1 2026
Wall Street & Market Data — Post May 11, 2026
| Metric / Source | View | Note |
|---|
| Simply Wall St — Analyst PT | Buy Consensus | $9.86 consensus target vs ~$4.95 stock · +99% implied upside |
| GF Score | 66 / 100 | Clinical-stage biotech risk profile · GF Value "Modestly Overvalued" (+1.2%) |
| Revenue growth consensus | +43% annually | 3-year forward · contingent on ABCL635 progression and partnership recovery |
| P/S vs. industry | 20.1x vs 3.5x | Significant premium · justified only if Ph2 shows robust efficacy |
| Key catalyst | Q3 2026 | ABCL635 Ph2 top-line efficacy + safety data — make or break event |
| Total liquidity | $655M | No financing required to reach Q3 catalyst · key de-risking factor |
Earnings Verdict
Q3 Phase 2 Data Is Everything — ABCL635 Safety Profile Reduces the Biggest Risk
AbCellera's Q1 2026 report is fundamentally a clinical update with financial context. The revenue beat ($8.3M vs $7.55M) and EPS beat (−$0.14 vs −$0.20) are secondary to the single most important development of the quarter: positive Phase 1 interim data for ABCL635. No liver toxicity — the most feared adverse event that has hampered the competing small molecule NK3R antagonist Fezolinetant (Veozah) — is the clearest possible de-risking signal for the antibody modality. Robust NK3R target engagement across three dose levels confirms the biology is working. The Phase 2 has been initiated, and top-line efficacy data are on track for Q3 2026. With $655M in total liquidity and no financing requirement before the readout, AbCellera enters the most important clinical event in its history from a position of financial strength. The investment case is binary: if ABCL635 demonstrates statistically significant reduction in hot flash frequency in Phase 2, the drug becomes a legitimate first-in-class long-acting injectable therapy in the large and underserved menopausal symptom market. If Phase 2 fails, the stock collapses toward cash value regardless of the platform business. The analyst consensus price target of $9.86 — nearly double the current ~$4.95 price — reflects the expected value of success. Q3 2026 efficacy data is the only catalyst that matters this year. Next earnings August 2026.